Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Morning gains eroded by the end
Wed, 25 Feb Closing

After starting the day on a firm note, selling activity intensified during the final two hours thereby wiping out all of the gains seen at the start of the day. The BSE-Sensex closed flat, up by about 3 points while the NSE-Nifty closed higher by about 5 points. Stocks from the healthcare and banking spaces were amongst the key losers today. Midcaps and smallcaps closed the day on a weak note with the indices ending lower by about 0.2% to 0.4%.

Asian stocks ended the day on a firm note; stocks in Europe were trading mixed at the time of writing. The rupee was trading at Rs 62.05 to the dollar.

Auto stocks ended the day on a weak note with Eicher Motors, Hero Motocorp and Bajaj Auto leading the pack of losers. The stock of TVS Motor Company has been under pressure of late. The stock has fallen by about 17% from its 52-week high which it touched around mid January this year. While the company reported as strong set of numbers in its results (revenues and profits up by 30% YoY and 31% YoY respectively) for the quarter ended December 2014, the stock continues to witness selling pressures over the past few weeks. It seems one of the concerns of the investors has been the sale of 1.5 m shares, amounting to Rs 45 crores, by the company's promoter Venu Srinivasan recently. This represents about 0.32% of the company's total shares. The transaction was done at a price of Rs 298. Today, the stock closed at about Rs 273, a figure lower by 8% from the sale price. At the end of December 2014, the company's promoters held 57.4% stake in the business.

Stocks of pharmaceutical companies ended the day on a weak note with Strides Arcolab, Dr. Reddy's and Apollo Hospitals leading losses. As reported by the Hindu Business Line, pharma major Glenmark Pharmaceuticals has announced that it has received USFDA approval to launch the generic version of Ashlyna contraceptive pills in the US market. These tablets are generic equivalents of Teva Women's Health's Seasonique tablets. The total annual sale of the latter stood at about US$ 159 m as on Dec 2014. The company plans to begin shipping the product immediately. Glenmark already has an established portfolio in oral contraceptive space in US. Glenmark's current US portfolio consists of 94 products authorised for distribution in the US and 75 ANDA's are still pending for approval with the US health regulator. The stock ended the day lower by about 2.4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Morning gains eroded by the end". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.